Introduction
============

Antiretroviral therapy (ART) has transformed HIV infection from a death sentence to a long-term condition and, as patients live longer, noncommunicable diseases (NCDs) are becoming increasingly important illnesses among these patients. Individual care models in Europe predict that 84.0% of HIV infected individuals receiving ART will have at least one NCD comorbidity by the year 2030 \[[@R1]\] with comorbidities most significant among older patients \[[@R2]\]. Studies in high-income countries and recently published data from Sub-Saharan Africa confirm a high prevalence of noninfectious comorbidities among the HIV infected \[[@R3],[@R4]\].

HIV infection itself, independent of ART, has been linked to cardiovascular disease (CVD), as well as several organ system dysfunctions \[[@R5]\]. Yet, research also suggests that ART can be a risk factor for NCDs like CVD \[[@R6],[@R7]\] and diabetes \[[@R8],[@R9]\], with HIV-infected individuals on ART twice as likely to have CVD as their HIV-negative counterparts \[[@R10]\]. Even in patients on treatment who achieve adequate viral suppression and high CD4^+^ cell counts, there is increasing evidence that low-level chronic inflammation may still play a part in morbidity and mortality over the long term \[[@R11]--[@R13]\].

In Malawi, previous study has established that 36% of CVD-related deaths and 45% of cardiac disease and hypertension-related deaths were among HIV-positive individuals \[[@R14]\]. The prevalence of risk factors for CVD and CVD-related mortality are also high in Malawi, with 33 and 14% of participants in a nationwide survey reporting hypertension and cigarette smoking, respectively \[[@R15]\]. And though CVD risk factors have previously been described among adult HIV-positive people on ART in some Sub-Saharan contexts \[[@R16]--[@R18]\], data are still lacking in of the continent among aging HIV patients who have been taking ART for long periods of time. This is further complicated by growing concerns that the multimorbidity associated with living with HIV disease will impact healthcare systems in the resource-limited countries that have yet to develop and implement a chronic care model. We measured the prevalence of elevated cholesterol, diabetes, hypertension, smoking, and elevated BMI among HIV-positive patients receiving ART years for more than 10 years.

Methodology
===========

The cross-sectional survey of HIV-infected patients on ART for more than 10 years occurred in two Médecins Sans Frontières (MSF)-supported facilities between November 2015 and June 2016 in Chiradzulu District, in southern Malawi (population 291 000) which has an HIV prevalence of 17% \[[@R19],[@R20]\]. MSF has been working in Chiradzulu district since 1997, started providing ART in 2001, and has been supporting decentralized care since 2006 \[[@R21]\]. Two facilities (Bilal health center and Chiradzulu district hospital) with large proportions of long-term ART patients were selected as study sites. HIV-positive individuals who were at least 30 years old and on ART for more than 10 years in Chiradzulu district (patients), and HIV-negative individuals at least 30 years living in Bilal and Chiradzulu hospital catchment areas (controls) were considered eligible.

The MSF follow-up and care of HIV infection and AIDS database (Epicentre, Paris, France) was used to generate a daily list of eligible patients who were then invited to participate in the study. Controls were matched to the patient cohort by sex. Community awareness about the study objectives and scope was conducted in meetings with key community leaders and groups. These sessions were also used to invite controls to participate in the research, encouraging them to go to the study clinics for screening and possible inclusion.

Data collection and variables
-----------------------------

Demographic data, medical history, and physical examination findings were recorded on the day of inclusion into the study using a standard case report form. Demographic data collected included sex, age, level of education, occupation, and marital status. Physical examination findings included SBP and DBP, weight, and height. BMI was define as underweight (BMI \< 18.5 kg/m^2^), normal (BMI 18.5 to 24.9), overweight (BMI 25.0 to 29.9), and obese (BMI ≥30). High blood pressure (BP) was defined as a SBP of at least 140 mmHg, a DBP of at least 90 mmHg, or both \[[@R22],[@R23]\]. The Korotkoff technique was used to measure BP over the brachial artery using an aneroid sphygmomanometer with an adult cuff \[[@R23]\]. The patient sat in upright position in a quiet room. Two consecutive BP measurements were taken and the average recorded as the final result. The BP was measured on the day of enrolment into study.

Blood was collected on the day of inclusion to be tested for the following measures: glycated hemoglobin (HbA1c), lipid profile, total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides. Analysis was performed on the BS120 Mindray (Nanshan, People\'s Republic of China) at Queen Elizabeth Central Hospital Laboratory in Blantyre, Malawi. CD4^+^ cell counts were measured using Partec CyFlow Counter (Cyflow SL, Partec, Munster, Germany), whereas semiquantitative viral-load measurements were performed using the simple amplification-based assay semiquantitative test for HIV-1, SAMBA (Diagnostics for the Real World, Sunnyvale, California, USA). Viral load and CD4^+^ tests were performed at the Chiradzulu District Hospital laboratory. To confirm HIV-negative status, controls received HIV testing following the Ministry of Health Malawi guidelines \[[@R24]\]. A serial algorithm with Determine Rapid HIV-1/2 antibody (Abbott Laboratories, Abbott Park, Illinois, USA) followed by Unigold Rapid HIV Test (Trinity Biotech, PLC, IDA Business Park, Bray, County Wicklow, Ireland) was used.

Cutoff points considered as being risk factors for CVD were TC at least 200 mg/dl, HDL less than 40 mg/dl (men) and less than 50 mg/dl (women), LDL of at least 130 mg/dl, and triglycerides at least 150 mg/dl \[[@R25],[@R26]\]. For diabetes, HbA1c of 6.0--6.4% was considered prediabetes and levels at least 6.5% were indicative of diabetes \[[@R27]\]. Diabetes status was also established using a self-reported history or use of antidiabetic medication.

The Framingham 10-year risk of CVD, the Framingham risk score (FRS) was calculated using the formula from the Framingham Heart Study \[[@R28],[@R29]\]. Variables used in the FRS calculation were sex, age, SBP, current treatment of hypertension, current smoking status, HDL and TC, and diabetes.

Analysis
--------

Study data were double entered and managed using Research Electronic Data Capture (REDCap, Vanderbilt University). Statistical analysis was performed in Stata 13 (College Station, Texas, USA). The demographic and cardiovascular risk factors were described separately for patients and controls and were stratified by age. The prevalence of hypocholesteremia, diabetes, hypertension, and other CVD risk factors were reported with 95% confidence intervals (CI). Means with their SDs, or medians with corresponding interquartile ranges (IQR) were calculated for continuous variables, and frequencies and proportions were established for categorical data. Univariate and multivariate logistic regressions models were used to assess factors associated with elevated LDL cholesterol (cutoff at 130 mg/dl), and elevated HbA1c (cutoff at 6.0%). Multivariate analyses were adjusted by HIV status (patient or control), age group, sex, education, and BMI.

Ethics
------

Ethical approval was granted in Malawi by the National Health Sciences Research Committee (ref 1359). Each participant provided written informed consent to participate in the study. The study was conducted in accordance with the Helsinki Declaration on ethical principles for medical research involving human study participants.

Results
=======

Characteristics of participants
-------------------------------

A total of 379 HIV-positive (patients) and 356 HIV- negative (controls) were included in the study (Fig. [1](#F1){ref-type="fig"}).

![Inclusion flow chart.](aids-32-253-g001){#F1}

Women made up 73.0% of patients (*n* = 281) and 73.3% of controls (*n* = 261). HIV patients were younger than controls \[median age 47 years (IQR 42--52) vs. 52 years (IQR 40--63)\]; Table [1](#T1){ref-type="table"}), had higher educational attainment (30.8 vs. 13.0%, *P* \< 0.001), more skilled work (29.6 vs. 14.7%, *P* \< 0.001), and were more often divorced (18.8 vs. 10.4%, *P* \< 0.001) or widowed (26.5 vs. 18.9%, *P* \< 0.001).

###### 

Baseline characteristics of patients and controls stratified by age.

                                 Patients            Controls                                                                                                                
  ------------------------------ ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  Sex                                                                                                                                                                        
   Female                        86.3 (79.5--91.1)   67.3 (60.6--73.5)   55.3 (39.4--70.1)   73.1 (68.4--77.3)   72.4 (63.6--79.8)   80.2 (72.1--86.4)   67.2 (58.3--75.1)   73.3 (68.5--77.7)
   Male                          13.7 (8.9--20.5)    32.7 (26.6--39.5)   44.7 (29.9--60.6)   26.9 (22.7--31.6)   27.6 (20.2--36.4)   19.8 (13.7--27.9)   32.8 (24.9--41.7)   26.7 (22.3--31.6)
  Current residence                                                                                                                                                          
   In Chiradzulu district        81.3 (73.9--87.0)   68.8 (62.1--74.8)   68.4 (52.2--81.1)   73.3 (68.7--77.6)   99.1 (94.0--99.9)   97.5 (92.5--99.2)   100                 98.9 (97.0--99.6)
   Outside Chiradzulu district   18.7 (13.1--26.1)   31.2 (25.2--37.9)   31.6 (18.9--47.8)   26.7 (22.4--31.6)   0.9 (0.1--6.0)      2.5 (0.8--7.5)      0                   1.1 (0.4--3.0)
  Education                                                                                                                                                                  
   Primary education or less     71.7 (63.6--78.6)   66.2 (59.3--72.4)   76.3 (60.4--87.2)   69.2 (64.4--73.7)   74.8 (66.0--81.9)   91.7 (85.3--95.5)   94.1 (88.2--97.2)   87.0 (83.1--90.2)
   Secondary education or more   28.3 (21.4--36.4)   33.8 (27.6--40.7)   23.7 (12.8--39.6)   30.8 (26.3--35.6)   25.2 (18.1--34.0)   8.3 (4.5--14.7)     5.9 (2.8--11.8)     13.0 (9.8--16.9)
  Occupation                                                                                                                                                                 
   Unskilled work                74.8 (66.9--81.4)   63.9 (57.0--70.2)   89.5 (75.1--96.0)   70.5 (65.6--74.9)   82.8 (74.8--88.6)   81.0 (73.0--87.0)   92.4 (86.0--96.0)   85.4 (81.3--88.7)
   Skilled work                  25.2 (18.7--33.1)   36.1 (29.8--43.0)   10.5 (4.0--24.9)    29.6 (25.2--34.4)   17.2 (11.4--25.2)   19.0 (13.0--27.0)   7.6 (4.0--14.0)     14.7 (11.3--18.7)
  Marital status                                                                                                                                                             
   Never married                 1.4 (0.4--5.6)      0.5 (0.1--3.5)      0                   0.8 (0.3--2.4)      2.6 (0.8--7.8)      0                   0                   0.8 (0.3--2.6)
   Married                       56.1 (47.7--64.2)   54.7 (47.7--61.5)   42.1 (27.6--58.1)   54.0 (48.9--59.0)   78.5 (70.0--85.0)   76.0 (67.6--82.8)   55.1 (46.0--63.8)   69.9 (64.9--74.4)
   Divorced                      23.7 (17.4--31.6)   16.2 (12.3--22.8)   10.5 (4.0--25.0)    18.8 (15.1--23.1)   13.8 (8.6--21.4)    9.1 (5.1--15.7)     8.5 (4.6--15.1)     10.4 (7.6--14.1)
   Widowed                       18.7 (13.0--26.1)   27.9 (22.1--34.5)   47.4 (32.1--63.1)   26.5 (22.2--31.2)   5.2 (2.3--11.1)     14.9 (9.6--22.4)    36.4 (28.2--45.5)   18.9 (15.1--23.3)
  Toilet                                                                                                                                                                     
   Nonimproved facility          64.8 (56.4--72.3)   48.5 (41.7--55.4)   57.9 (41.9--72.4)   55.4 (50.3--60.4)   84.4 (76.7--90.0)   80.2 (72.1--86.4)   83.2 (75.4--88.9)   82.6 (78.3--86.2)
   Improved facility             35.3 (27.8--43.6)   51.5 (44.6--58.3)   42.1 (27.6--58.1)   44.6 (39.6--49.7)   15.5 (10.0--23.3)   19.8 (13.7--27.9)   16.8 (11.1--24.6)   17.4 (13.8--21.7)

CI, confidence interval.

The median time on ART for patients was 11.6 years (IQR 10.6--12.4). Initial ART regimens were all composed of two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitors (NNRTIs); mainly stavudine (88.7%), lamivudine (100%), and nevirapine (97.9%). At the time of the study, 90.5% (*n* = 343) of the patients were on first line, 9.2% (*n* = 35) on second line, and 0.3% (*n* = 1) on third line. Fixed dose combination based on tenofovir, lamivudine (3TC), and efavirenz was the most common first line (86.6%). Among patients, 92.7% (95% CI 90.6--94.4) had a viral load less than 1000 copies/ml and 61.3% (95% CI 56.2--66.1) had a CD4^+^ at least 500 cells/μl.

Prevalence of cardiovascular disease risk factors
-------------------------------------------------

Prevalence of CVD risk factors are presented in the Table [2](#T2){ref-type="table"}. Smoking was low among patients (2.4%; 95% CI 1.2--4.5) and controls (5.1%; 95% CI 3.2--7.9), though men were more likely to smoke than women among both HIV patients (5.9 vs. 1.1%; *P* \< 0.01) and controls (13.7 vs. 1.9%, *P* \< 0.01). The proportion of HIV patients considered overweight or obese (BMI above or equal to 25 kg/m^2^) was 17.3% (95% CI 11.8--24.5), 20.8% (95% CI 15.7- 27.0), and 10.5% (95% CI 4.0--24.9) among the 30--44, 45--59, and at least 60 years age groups, respectively. Among the controls it was 21.7% (95% CI 15.1--30.2), 30.0% (95% CI 22.5--38.8), and 16.0% (95% CI 10.4--23.7). Women had significantly higher proportions with a BMI at least 25 kg/m^2^; among patients (22.0 vs. 8.8%, *P* = 0.01), and controls (27.4 vs. 9.5%, *P* \< 0.01), as well as higher rates of abnormal waist--hip ratio among patients (52.4 vs. 12.8%, *P* \< 0.001) and controls (44.1 vs. 3.2%, *P* \< 0.001).

###### 

Prevalence of cardiovascular risk factors among patients and controls stratified by age.

                                           Patients            Controls                                                                                                                   
  ---------------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------- --------------------- -------------------
  BMI (kg/m^2^):                                                                                                                                                                          
   Overweight (≥25 \< 30)                  15.1 (10.1--22.1)   12.4 (8.5--17.7)    5.3 (1.3--18.8)     12.7 (9.7--16.4)    14.8 (9.4--22.5)    18.3 (12.4--26.3)    12.6 (7.7--19.9)      15.3 (11.9--19.4)
   Obese (≥30)                             2.2 (0.7--6.5)      8.4 (5.3--13.1)     5.3 (1.3--18.8)     5.8 (3.8--8.7)      7.0 (3.5--13.3)     11.7 (7.0--18.8)     3.3 (1.3--8.6)        7.3 (5.0--10.6)
  Waist--hip ratio                                                                                                                                                                        
   \>0.95 (male) and \>0.85 (female)       41.0 (33.1--49.4)   42.1 (35.5--49.0)   42.1 (27.6--58.1)   41.7 (36.8--46.7)   30.2 (22.5--39.1)   38.8 (30.6--47.8)    30.3 (22.7--39.1)     33.2 (28.4--38.2)
  SBP (mmHg):                                                                                                                                                                             
   140--159                                1.4 (0.4--5.6)      9.5 (6.1--14.4)     31.6 (18.9--47.8)   8.7 (6.3--12.0)     3.5 (1.3--9.0)      17.5 (11.7--25.4)    24.4 (17.5--32.9)     15.3 (11.9--19.5)
   160--179                                1.4 (0.4--5.6)      4.5 (2.3--8.4)      2.6 (0.4--16.5)     3.2 (1.8--5.5)      0                   5.8 (2.8--11.8)      9.2 (5.2--15.9)       5.1 (3.2--8.0)
   ≥180                                    0                   1.0 (0.2--3.9)      5.3 (1.3--18.8)     1.1 (0.4--2.8)      0                   0                    7.5 (4.0--13.9)       2.5 (1.3--4.8)
  SBP ≥140 mmHg                            2.9 (1.1--7.4)      14.9 (10.6--20.6)   39.5 (25.4--55.6)   13.0 (9.9--16.8)    3.5 (1.3--9.0)      23.3 (16.6--31.7)    41.2 (32.7--50.2*)*   23.0 (18.9--27.6)
  DBP (mmHg)                                                                                                                                                                              
   90--99                                  8.6 (5.0--14.6)     11.9 (8.1--17.2)    15.8 (7.3--31.0)    11.1 (8.3--14.7)    6.1 (3.0--12.3)     13.3 (8.3--20.7)     19.3 (13.2--27.4)     13.0 (9.9--17.0)
   100--109                                1.4 (0.4--5.6)      4.5 (2.3--8.4)      10.5 (4.0--24.9)    4.0 (2.4--6.5)      0                   4.2 (1.7--9.6)       5.9 (2.8--11.8)       3.4 (1.9--5.9)
   ≥110                                    0                   1.5 (0.5--4.5)      2.6 (0.4--16.5)     1.1 (0.4--2.8)      0                   0                    5.9 (2.8--11.8)       2.0 (0.9--4.1)
   DBP ≥90 mmHg                            10.1 (6.0--16.3)    17.9 (13.2--23.9)   29.0 (16.8--45.1)   16.1 (12.8--20.2)   6.1 (3.0--12.3)     17.5 (11.7--25.4)    31.1 (23.4--40.0)     18.4 (14.7--22.8)
   Hypertension (BP ≥140/90 mmHg)          10.8 (6.6--17.2)    20.4 (15.4--26.6)   44.7 (29.9--60.6)   19.3 (15.6--23.6)   6.1 (3.0--12.3)     25.8 (18.8--34.4)    42.9 (34.3--51.9)     25.2 (21.0--30.0)
  Self- reported history of hypertension   5.0 (2.4--10.2)     14.1 (9.9--19.4)    34.2 (21.0--50.5)   12.8 (9.7--16.6)    9.2 (5.0--16.2)     32.1 (24.2--41.3)    37.6 (29.3--46.7)     26.6 (22.2--31.6)
  Total cholesterol                                                                                                                                                                       
   ≥200 mg/dl:                             10.1 (6.1--16.4)    19.8 (14.9--25.9)   26.3 (14.8--42.1)   16.9 (13.5--21.1)   2.6 (0.8--7.9)      16.7 (11.0--24.5)    17.7 (11.8--25.6)     12.5 (9.4--16.4)
   Median TC: mg/dl (IQR)                  140.5 (110--175)    154 (118--187)      166 (137--202)      151 (115--181)      131 (103--169)      152 (115.5--186.5)   148 (114--185)        144 (111--180)
  LDL cholesterol                                                                                                                                                                         
   ≥130 mg/dl:                             8.0 (4.5--13.9)     15.4 (11.1--21.1)   23.7 (12.8--39.6)   13.6 (10.5--17.4)   1.8 (0.4--6.8)      12.5 (7.7--19.7)     11.8 (7.1--18.9)      8.8 (6.2--12.2)
   Median LDL (IQR)                        77 (59--104)        88 (65--116)        96.5 (66--128)      85 (63--111)        71.5 (55--92)       86.5 (63.5--110)     84 (63--109)          80 (61--106)
  HDL cholesterol                                                                                                                                                                         
   \<40 (male)/\<50 (female)               53.6 (45.3--61.8)   49.0 (42.1--55.9)   34.2 (21.0--50.5)   49.2 (44.1--54.3)   57.0 (47.8--65.8)   52.5 (43.6--61.3)    49.6 (40.7--58.5)     53.0 (47.7--58.1)
   Median HDL female (IQR)                 45 (35--60)         47 (34--65)         60 (43--69)         47 (35--63)         46 (35--54)         46 (35.5--58)        45.5 (33--59)         46 (35--58)
   Median HDL male (IQR)                   46 (35--62)         46 (39--59)         45 (31--62)         46 (38--60)         41.5 (32--54)       46.5 (32--58.5)      43 (32--57)           43 (32--57)
  Triglycerides                                                                                                                                                                           
   ≥150 mg/dl                              13.0 (8.3--19.6)    19.3 (14.4--25.4)   10.5 (4.0--24.9)    16.1 (12.7--20.2)   7.8 (4.1--12.3)     19.0 (13.0--27.0)    12.6 (7.7--19.9)      13.2 (10.1--17.1)
   Median TG (IQR)                         76 (48--116)        88.5 (63--129)      87.5 (65--132)      84 (60--126)        77.5 (53--105)      92 (63.5--132.5)     91 (69--121)          66 (63--121)
  HbA1c                                                                                                                                                                                   
   6.0--6.4%                               6.5 (3.4--12.0)     7.9 (4.9--12.6)     10.5 (4.0--24.9)    7.7 (5.4--10.8)     3.5 (1.3--8.8)      5.8 (2.8--11.8)      6.8 (3.4--13.0)       5.4 (3.4--8.3)
   ≥6.5%                                   5.0 (2.4--10.2)     6.4 (3.8--10.8)     13.2 (5.6--28.0)    6.6 (4.5--9.6)      3.4 (1.3--8.8)      4.2 (1.7--9.6)       1.7 (0.4--6.5)        3.1 (1.7--5.5)
  Current smoker                                                                                                                                                                          
                                           2.2 (0.7--6.5)      2.5 (1.0--5.8)      2.6 (0.4--16.5)     2.4 (1.2--4.5)      2.6 (0.8--7.7)      4.1 (1.7--9.6)       8.4 (4.6--14.9)       5.1 (3.2--7.9)

BP, blood pressure; CI, confidence interval; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; TC, total cholesterol; TG, triglycerides.

Among HIV patients, the prevalence of hypertension was 19.5% (95% CI 15.6--23.6), of which 60.3% (*n* = 44) was previously undiagnosed. Stratified by age group, 10.8% (95% CI 6.6--17.2), 20.4% (95% CI 15.4--26.6), and 44.7% (95% CI 29.9--60.6) of HIV patients' hypertension was undiagnosed in the 30--44, 45--59, and at least 60 years age groups, respectively. Among controls, 25.8% (95% CI 21.6--30.7) and among these 37.0% (*n* = 30) of hypertension was previously undiagnosed. In controls, 6.1% (95% CI 3.0--12.3), 25.8% (18.8--34.4), and 42.9% (95% CI 34.3--51.9) of hypertension was undiagnosed in the 30--44, 45--59, and at least 60 years age groups, respectively.

The proportion of elevated LDL cholesterol was higher among HIV patients \[13.6% (95% CI 10.5--17.4) vs. 8.9% (95% CI 6.2--12.2)\]. Patients who were initiated on ART with a regimen including stavudine had higher frequencies of abnormal LDL compared with those who were initiated with zidovudine (14.7 vs. 2.5%, *P* = 0.03). In the multivariate analysis, an LDL of at least 130 mg/dl; was significantly associated with having a secondary education or more \[adjusted odds ratio (aOR) 2.4; 95% CI 1.4--4.3\] and being overweight or obese, (aOR 3.4; 95% CI 1.9--5.8; Table [3](#T3){ref-type="table"}).

###### 

Association between LDL cholesterol, glycated hemoglobin with key risk factors: multivariate logistic models.

                        OR of LDL ≥130 mg/dl   OR of HbA1c ≥6.0%                    
  --------------------- ---------------------- ------------------- ---------------- ----------------
  Type of participant                                                               
   Control              1                      1                   1                1
   Patient              1.6 (1.0--2.6)         1.7 (1.0--3.0)      1.8 (1.1--2.9)   2.1 (1.2--3.5)
  Age group                                                                         
   30--44               1                      1                   1                1
   45--59               3.0 (1.6--5.8)         2.9 (1.5--5.7)      1.4 (0.8--2.4)   1.3 (0.8--2.3)
   ≥60                  3.1 (1.5--6.4)         5.1 (2.3--11.1)     1.3 (0.7--2.5)   1.8 (0.9--3.6)
  Sex                                                                               
   Female               1                      1                   1                1
   Male                 1.2 (0.7--2.0)         1.0 (0.6--1.8)      0.8 (0.5--1.4)   0.8 (0.5--1.5)
  Education                                                                         
   Primary or less      1                      1                   1                1
   Secondary or more    2.7 (1.7--4.4)         2.4 (1.4--4.3)      1.2 (0.7--2.0)   1.0 (0.6--1.8)
  BMI                                                                               
   Normal               1                      1                   1                1
   Underweight          0.9 (0.4--1.8)         0.8 (0.4--1.8)      0.8 (0.4--1.6)   0.7 (0.3--1.4)
   Overweight/obese     3.4 (2.0--5.6)         3.4 (1.9--5.8)      1.6 (1.0--2.7)   1.6 (0.9--2.8)

CI, confidence interval; HbA1c, glycated hemoglobin; OR, odds ratio.

Four patients (1.1%; 95% CI 0.4--2.8) and two controls (0.6%; 95% CI 0.1--2.3) had a known diabetes diagnoses at study inclusion. The prevalence of diabetes was 6.6% (95% CI 4.5--9.6) among HIV patients and 3.1% (95% CI 1.7--5.5) in controls. There was a higher proportion of patients at least 60 years with an HbA1c at least 6.5% compared with controls in the same age group; 13.2% (95% CI 5.6--28.0) vs. 1.7% (95% CI 0.4--6.5), respectively (Table [2](#T2){ref-type="table"}). In the multivariate analysis, HIV patients were more likely than controls to have an HbA1c at least 6.0% (aOR 2.1; 95% CI 1.2--3.5) Table [3](#T3){ref-type="table"}.

Framingham risk score
---------------------

Among patients, the prevalence of FRS more than 20% in the 30--44, 45--59, and at least 60-year age groups was 0.7% (95% CI 0.1--5.0), 2.5% (95% CI 1.1--6.0), and 23.7% (95% CI 12.8--39.6), respectively, compared with 0, 3.3 (95% CI 1.2--8.6), and 23.5% (95% CI 16.8--32.0) among controls. Among all study participants, the proportion of FRS at least 20% was significantly higher in men compared with women (10.9 vs. 1.5%, *P* \< 0.01 in HIV patients; 23.7 vs. 3.9%, *P* \< 0.001 in controls), and among those with at least a secondary education when compared with those with at most a primary education (9.6 vs. 1.6%, *P* \< 0.01 in HIV patients; 13.3 vs. 8.6%, *P* \< 0.01) (Fig. [2](#F2){ref-type="fig"}).

![Framingham 10-year risk of CVD stratified by age and sex.](aids-32-253-g002){#F2}

Discussion
==========

Our results show an aging cohort of HIV patients who, after taking ART over more than a 10-year period, had a disproportionate burden of CVD risk factors. To our knowledge, it is the first study from Sub-Saharan Africa to describe CVD risks among the HIV-infected exposed to uninterrupted ART for such a long period of time. In Malawi, these patients had a two-fold higher prevalence of diabetes and a high prevalence of hypercholesterolemia, suggesting that long-term exposure to ART increased patients' risk profiles, especially among older patients.

We found no significant difference in the 10-year risk of developing CVD between patients and controls, deviating from European studies where HIV patients on ART were observed to be more at risk of developing CVD \[[@R30]\]. Differences between our findings and European studies may be partially explained by the different ART regimens used. In Europe, regimens which include protease inhibitors are commonly used compared to Malawi were NNRTIs are used in more than 90% of cases \[[@R31],[@R32]\]. The use of protease inhibitors increases the risk of some key CVD risk factors such as cholesterol when compared to NNRTIs \[[@R7]\]. Additionally, in Europe HIV is mainly found in key subpopulations such as MSM or people who inject drugs who also have a significant burden of other key CVD risk factors like smoking or hepatitis C \[[@R33]--[@R35]\]. In Malawi, the more generalized HIV epidemic more closely reflects the general population\'s CVD risk factors, softening differences between HIV infected and the uninfected. All the same, men in both groups had a significantly a higher prevalence of Framingham risk score more than 20% compared to women, similar to findings from Uganda \[[@R36],[@R37]\]. As HIV-positive men in Malawi have poorer health-seeking behaviors overall than women \[[@R19]\], our findings reinforce the need to tailor programs that improve the access of men to healthcare services regardless of their HIV status. Risks associated with sex were not limited to men in our study. Female study participants exhibited significantly higher proportions of abnormal waist-to-hip ratios and abnormal BMI, perhaps related to sociocultural perceptions surrounding obesity \[[@R38]--[@R40]\]. A larger body size is often associated with wealth and well-being in this context without concurrent understanding of the health risks of being overweight. Further study of the interaction of obesity, HIV, and health outcomes in the Malawi context are warranted.

Men also reported higher frequencies of smoking, although smoking rates were lower in HIV patients overall, perhaps because of healthy lifestyle messages given during clinical or counselling interactions, or because of poorer economic conditions. The prevalence of smoking among all study participants was lower than rates reported in national surveys, a surprising finding in Chiradzulu as national surveys also have reported higher rural rates of smoking when compared to urban centers \[[@R41]\].

Our study identified a clear gap in the identification and management of chronic comorbidities especially diabetes and hypertension, in all study participants. High prevalence rates of undiagnosed diabetes were previously described in Malawi and Sub-Saharan Africa setting \[[@R42],[@R43]\]. Undiagnosed hypertension has also been described in other similar contexts \[[@R41],[@R44],[@R45]\]. Yet, our study found that HIV patients' undiagnosed hypertension was 23% higher than controls despite the fact that, during the course of their HIV management, they had at least one contact with the health system every 3--6 months. Routine HIV follow-up care provides many opportunities for screening for hypertension and other CVD and risk factors, as well as for managing hypertensive disorders and other NCDs. The proportion of hypertensive individuals significantly increased with age among all study participants, although it remained lower than the 33% observed in a Malawi national survey \[[@R15]\]. We observed that the largest proportion of hypertensive participants had stage 1 hypertension. As there is no evidence of reducing cardiac events and mortality through treatment of stage 1 hypertension \[[@R46]\], it may be prudent to focus treatment on high risk older or severely hypertensive patients and actively monitoring the rest, considering the limited human and material resources available in this context \[[@R42]\].

We found a high prevalence of LDL cholesterol which increased significantly with age. The prevalence of hypercholesterolemia among our study patients was higher than that observed among the general population \[[@R41]\]. Other studies in Sub-Saharan Africa found higher hypercholesterolemia rates among HIV patients when compared to ours \[[@R18],[@R47]--[@R50]\]. Higher proportions of hypercholesterolemia were also observed to be associated with a variety of factors including the patient being ART experienced (vs. ART naive) \[[@R51],[@R52]\] or having prolonged exposure to the drugs stavudine and efavirenz \[[@R53],[@R54]\]. The lower prevalence of hypercholesterolemia observed in our study compared to other contexts may be partially explained by the different ART regimens used by the patients; most of our study patients had at least 3 years exposure to the less toxic tenofovir-based regimen at the time of study inclusion.

Findings from this study should be considered within the context of its limitations. Though we had a low refusal rate, reducing the risk of selection bias, we cannot rule out information bias as participants may have given socially acceptable responses, for example, on smoking status. There are other lifestyle variables we did not explore in this study which may be possible sources of confounding in the association between HIV status and CVD risk factors. For the Framingham risk score calculation, we used HbA1c as a measure of diabetes and made the assumption that none of the patients or controls had an existing cardiac problem, thus overestimates of at risk individuals may not be ruled out.

In conclusion, there are clearly unmet needs in the diagnosis and management of NCDs among both HIV patients and in uninfected community members in Chiradzulu, and CVD risk factor screening and NCD treatment should be an area of focus for HIV actors in Malawi. Sex differences found here demand that interventions target men and women differently, especially male smokers and overweight women, and that men\'s overall higher 10-year CVD risk and poorer HIV health-seeking behaviors be acknowledged. Our findings highlight the need to implement screening and treatment of diabetes, hypertension, and hypercholesterolemia for at risk, HIV-infected individuals on ART. However, they also serve as a reminder that CVD risk is not limited to those with HIV, and that at risk uninfected individuals, especially older community members, have NCD screening and treatment needs as well.
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